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This study aims to assess the autoimmunological status and forms of celiac disease (CD) among children with type 1 diabetes
mellitus(T1DM).Thestudygroupcomprises27patientsatthemeanageof12.30years(±SD3.12).Themeasurementofthelevel
of diabetes-speciﬁc antibodies and organ-speciﬁc antibodies was gained at the T1DM-onset and repeated annually. The following
risk factors inﬂuencing time of CD diagnosis were analyzed: age, sex, T1DM duration, autoantibodies, and HLA-haplotype. The
prevalence of antibodies was GADA-74%, IAA-63%, IA2A-67%, ATA-11%, and ATG-4%. The intestinal biopsy revealed in 19%
no changes and in 77% stage 3 (Marsh scale). In most cases, no clinical manifestation of CD was observed. The diagnosis of
Hashimoto’s disease was made twice. The negative correlation between the age at T1DM-onset and the interval between onset of
T1DM and CD (r =− 0.35, p<. 05) was noted. The high-comorbidity ratio of CD and thyroiditis with T1DM demands regular
screening tests especially in the ﬁrst years after T1DM-onset.
Copyright © 2008 Grazyna Deja et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Due to a common genetic background and interaction be-
tween environmental and immunological factors, patients
with type 1 diabetes mellitus (T1DM) are at a high risk of
having other autoimmunological diseases. The autoimmune
polyendocrine syndromes type 1 (APS-1) and type 2 (APS-
2) are rare but most dramatic. APS-1 is caused by a sin-
gle mutation in the AIRE gene (transcriptional factor) as
opposite to APS-2, which is a “complex” genetic disorder
with strong HLA-genes association (haplotype DQA1∗0501,
DQB1∗0201, DRB1∗0301) [1]. Single autoimmune diseases
like celiac disease (CD) or thyroid gland disease are more
common among patients with T1DM. They are also con-
nected with above-mentioned predisposing HLA-genes. In
the course of T1DM, no clinical manifestation of both coex-
isting disorders is noted in most cases [2, 3]. That is why reg-
ular investigations of the autoimmunological status should
be provided. Severe complications of untreated celiac disease
necessitate an early diagnosis and the prompt introduction
of a gluten-free diet. Undiagnosed thyroid gland disease that
remains untreated can lead to subclinical or clinical obvious
hypothyroidism.
At the time of the diagnosis of diabetes, various antibod-
ies are evaluated. To make a statement of autoimmune back-
ground of the disease, the diabetes-associated antibodies are
detected. Blood samples are screened for islet cell antibodies,
insulin autoantibodies, GAD antibodies, and anti-IA-2 anti-
bodies [4, 5]. Additionally, screening for celiac disease and
autoimmune thyroiditis is usually performed. The presence
of humoral immune markers allows an immediate medical
intervention, but their absence should not mislead a physi-
cian, since there is a possibility of developing these disorders
some years after diabetes onset [5].
Thepurposeofourstudywastoassessretrospectivelythe
autoimmunological status from the time of the ﬁrst diabetes
presentation until celiac disease was revealed and assess the
risk factors of inﬂuencing the time of the CD diagnosis. The
next objective of the study was to evaluate the stages of celiac
diseasemostcommonlyappearingamongchildrenwithtype
1 diabetes mellitus.2 Mediators of Inﬂammation
2. MATERIALS AND METHODS
The study group comprises 27 diabetic children (14 girls, 13
boys) at the mean age of 12.3 years (±3.12) with diagnosed
celiac disease. They were selected from about 450 new pa-
tients with T1DM. The retrospective analysis concerns pa-
tients’ data collected in the years 2001–2006. All patients
taken into consideration were hospitalized in the Depart-
ment of Pediatrics, Endocrinology and Diabetes in Katowice
at the time of the ﬁrst diabetes presentation. Patients were
regularly observed in outpatient diabetes care at least till CD
was revealed. The diagnosis of T1DM was made according to
WHO and ISPAD criteria [4, 5].
The measurement of the level of disease-associated
autoantibodies to glutamic acid decarboxylase (GADA),
protein-tyrosine phosphatase (IA2A), insulin (IAA) was
gained at the time of T1DM onset. The serum samples were
drawn before the initiation of insulin treatment. Samples
for organ-speciﬁc antibodies: tissue transglutaminase (tTG),
thyroperoxidase (ATA), and thyroglobuline (ATG) as well
as thyroid hormones (TSH, fT4) were also obtained from
diabetes-onset patients. In all children, serum immunoglob-
ulin A (IgA) concentration was determined to exclude IgA
deﬁciency and a subsequent false interpretation of received
results of IgA tTG. The control measurements of tTG, ATG,
ATA,andthyroidhormoneswererepeatedannually.Thetiter
of GADA, IA2A, and IAA was gauged by using the radioim-
mune assay technique (RIA-CIS Bio International) in con-
formity with the protocols included in laboratory original
kits. The measurement ranges were as follows: for GADA 0–
300U/mL, for IA2A 0–50U/mL, and for IAA 0–100%. The
results for GADA and IA2A above 0.75U/mL and for IAA
above 7% were considered positive. The CD-associated IgA
tTG were detected by the ELISA method. The level of thy-
roid hormones and thyroid antibodies was estimated by the
chemiluminescence method (DPC, USA). Normal ranges for
fT4 for children under the age of 12 are 0.65–2.3ng/dl and
for older ones are 0.8–1.9ng/dl. TSH was assessed accord-
ing to age-adequate normal levels. The concentration of ATA
> 35IU/mL and of ATG > 40IU/mL was considered to be
positive. IgA concentration was assessed by immunoturbidi-
metric measurements (Dade Behring, Germany). IgA deﬁ-
ciencywasdeﬁnedasanIgAbelow-normalleveladequatefor
age.
If autoimmunity markers were present, the ultrasound
examination of thyroid gland or the small bowel biopsy was
ordered. Intestinal mucosa specimens were obtained during
peroral endoscopy and afterwards examined by a pathol-
ogist. Changes in mucosa were assessed by employing the
Marsh stage. Type 1 (inﬁltrative lesion) is characterized by
normal structure of mucosa with presence of intraepithelial
lymphocytes inﬁltration. Type 2 (hyperplastic lesion) com-
prises type 1-mentioned changes and additionally enlarged
jejunum crypts. Type 3 (destructive lesion) is divided into 3
groups. The characteristics of all of them include inﬂamma-
tory inﬁltration, hyperplastic crypts, and the villous atrophy,
w h i c hi ne a c hg r o u pi so fad i ﬀerent degree. In type 3a par-
tial, in type 3b subtotal, and in type 3c, total destruction of
villi is observed. Type 4 (hypoplastic lesion) comprises to-
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Figure 1: Diabetes-associated autoantibodies in children at the
time of T1DM onset.
tal villous atrophy without inﬂammatory inﬁltration and the
normal architecture of the crypts.
HLA tests were performed in the Regional Blood Cen-
tre in Katowice. HLA class II alleles were typed by using the
polymerasechainreaction—thesinglestrandpolymorphism
method (PCR-SSP). Allele-speciﬁc tests One Lambda (Cy-
togen, USA) were employed for HLA-DRB1∗ and DQB1∗
typing. For genetic assays, human leukocytes were used. The
PCR program was performed according to the protocol de-
scribed earlier [6].
The statistical analysis was carried out with the applica-
tion SigmaStat. To estimate the risk factors inﬂuencing the
time of CD diagnosis among children with T1DM, the fol-
lowing parameters were analyzed: age at T1DM onset, gen-
der, T1DM duration, presence of autoantibodies, and HLA
haplotype. The normality of the distribution of the contin-
uous variables was evaluated by using the Shapiro-Wilk test.
The correlation between analyzed parameters was calculated
by using Pearson correlation.The results with the p<. 05
were considered to be statistically signiﬁcant.
3. RESULTS
The mean age at T1DM diagnosis was 7.39 years (±SD 3.12),
and the mean age of CD diagnosis was 8.43 years (±3.69).
The prevalence of antibodies was as follows: GADA 74%,
IAA 63%, and IA2A 67%. One third (33%) of the probands
was tested positive for all three autoantibodies. In 11 (41%)
cases, the presence of two autoantibodies was identiﬁed. In
5 cases GADA+IA2A, in 4 cases GADA+IAA, and in 2 cases
IAA+IA2A were detected. Only in one case no autoantibod-
ies were detected (Figure 1).
Thyroid autoimmunity markers were present in 3 (11%)
children: 3 (11%) ATA and 1 (4%) ATG. All of them were
euthyroid. In 2 (7%) children, abnormal ultrasound thyroid
gland image was observed, suggesting Hashimoto’s disease.
In these children, therapy with L-thyroxine was introduced.
A total of 27 intestinal biopsies were performed. The biop-
sies revealed: 5 (19%) x no changes (latent form), 1 (4%) x
type 1, 6 (22%) x type 3a, 6 (22%) x type 3b, and 9 (33%) xGrazyna Deja et al. 3
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Figure 2: Negative correlation between age at T1DM-onset and the
interval between onset of T1DM and CD (r =− 0.35, p<. 05).
type 3c. In the case of 1 girl, CD 3a was present 3 years be-
fore she became diabetic. Only once were the T1DM and CD
diagnosis made at the same time. In most cases no clinical
manifestation was observed.
The HLA haplotypes were obtained from 24 diabetic
patients. Genetic typing results of HLA-DRB1 and DQB1
on the low-resolution level showed predominance of the
following haplotypes: DRB1∗04-DQB1∗03 and DRB1∗03-
DQB1∗02. These T1DM at-risk and CD at-risk haplotypes
were found in 8 cases (33%) and in 14 cases (59%), re-
spectively. In 6 patients (25%), both predisposed haplotypes
were detected. Two patients expressed DRB1∗03-DQB1∗02
homozygosity. There were no signiﬁcant diﬀerences in fre-
quency of haplotype in relation to sex, age at onset, diabetes
duration, or celiac disease form (see Table 1).
The analysis of the CD risk factors revealed negative cor-
relation between the interval between onset of T1DM-CD
and age at T1DM onset (r =− 0.35, p<. 05). There were
no other statistically signiﬁcant correlations between factors
taken into consideration (age, gender, T1DM duration, pres-
ence of autoantibodies, and HLA-haplotypes) (see Figure 2).
4. DISCUSSION
Our study supports the theory of elevated frequency rate
of appearance of other autoimmunological diseases in the
course of T1DM. The risk of celiac autoimmunity in certain
populations is as high as 1 in 100 [7, 8]. The prevalence of
celiac disease in children from our diabetes care is at about
6%, what is similar to other studies [8–11]. Moreover, 11%
ofstudiedchildrenhadthyroiditismarkers.Thelevelofcoex-
istence for thyroid- and CD-associated antibodies in diabetic
children was described in the previous studies at about 10%
[12] and at about 6% [13].
Celiac disease more and more often appears either as
symptomatic nonclassic or as a symptom-free disease [2, 3].
Asymptomatic CD can occur in a silent or latent form. An
equally predictive value characterizes most commonly pro-
vided serological tests for CD. These are the IgA endomysial
and/or IgA tissue transglutaminase antibodies. In our prac-
tice, we employ IgA tTG antibodies, which is well in ac-
cordance with the suggestions NASPGHAN guidelines from
2005 [14]. Also Kordonouri et al. indicate a positive predic-
tive value and higher than IgA EMA antibodies sensitivity in
patients with T1DM and silent CD [15].
All our patients with negative screening results at T1DM
onset were diagnosed to develop CD within 4 years. In other
investigations, the interval was as follows: 4 years [11]a n d
2y e a r s[ 16]. These results conﬁrm the importance of regu-
lar, annually performed control tests, especially in the ﬁrst
years after becoming diabetic. The asymptomatic course and
long exposition to gluten are probably the reason for such a
high frequency of Marsh 3c in our study group, as well as the
personal sensitivity and predispositions. We have only 1 girl
with CD diagnosed before T1DM onset. It conﬁrms other
authors’ observations that CD rarely precedes the presenta-
tion of T1DM [11, 17].
We found negative correlation between age at T1DM on-
set and the interval between onset of T1DM and CD. In the
case of other risk factors, such as age, gender, and T1DM du-
rationwedidnotobservestatisticallysigniﬁcantcorrelations.
The opinions of other authors about the risk factors of devel-
oping CD are inconsistent; some authors indicate females to
be at higher risk of having both diseases [2, 18].
The majority of cases of CD coexisting with T1DM are
symptom-free atCD-diagnosis [2, 3]. Often no signs of overt
malnutrition, no gastrointestinal symptoms, no dermatolog-
ical problems, or recurrent hypoglycemia episodes are noted
[2]. Also, the most of our patients did not present any symp-
toms of digestive system and no symptoms of malnutrition
and height deﬁciency. It is in accordance with the results
of the longitudinal observational study published by Valletta
et al. [19] which shows that at diagnosis of CD screened sub-
jectswithT1DMhadonlyminorsignsofmalnutrition(mea-
sured by weight, height and BMI). CD in our subjects was
conﬁrmed by a small bowel biopsy and a histological exami-
nation of intestinal specimens, which remains the gold stan-
dard method for the diagnosis [14]. In every positive subject
with diagnosed CD, a gluten-free diet was initiated. In chil-
drenwithadiagnosedlatentformofCD,serologicaltestsand
further clinical investigations areneeded since the overlap ei-
ther into a clinically overt or silent form of CD is possible.
Preventional treatment in the form of a gluten-free diet in
children with T1DM and silent CD also appears for us to be
justiﬁable [11, 20].
Autoimmune thyroiditis and T1DM can also frequently
coexistandtakeanunhomogeneouscourse.Itoftenstaysun-
d i a g n o s e db e c a u s eo fl a c ko fs y m p t o m s[ 21, 22]. In spite of
the presence of organ speciﬁc antibodies, such as thyroper-
oxidase and thyroglobuline, in about 20–30% patients with
diabetes, the rate of hypothyroidism is lower (5–10%), and
changes in the ultrasound image of thyroid gland are not fre-
quently observed. Polish studies also conﬁrm the high co-
morbidity of prevalenceofautoantibodies and thyroiddisor-
dersamongpatientswithT1DM[22,23].Inourgroupofpa-
tients with T1DM and CD, the analysis regarding thyroid au-
toimmunity revealed 3 (11%) patients with positive results.4 Mediators of Inﬂammation
Table 1: Study group characteristics.
Gender (female = 1) Age at T1DM onset GADA IAA IA2A ATA ATG Biopsy HLA
1 0 11.5 − ++++ 3 bD R B 1 ∗03 DQB1∗02 DRB1∗04 DQB1∗03
2 1 2.50 + + + −− 3b DRB1 07 DQB1 02 DRB1∗04 DQB1∗03
3 1 5.50 + − ++ − 3a DRB1∗03 DQB1∗02 DRB1∗16 DQB1∗05
4 0 5.00 − + −−− 0D R B 1 ∗03 DQB1∗02 DRB1∗04 DQB1∗03
5 0 10.00 + + −−− 1—
6 1 5.50 + + −−− 0—
7 0 2.50 + + + −− 3c DRB1∗03 DQB1∗03 DRB1∗04 DQB1∗02
8 1 5.50 − ++−− 3a DRB1 07 DQB1 03 DRB1 16 DQB1 06
9 1 7.00 + −−−− 3c DRB1∗03 DQB1∗02 DRB1∗04 DQB1∗03
10 0 3.00 + + + −− 0D R B 1 ∗03 DQB1∗02 DRB1∗04 DQB1∗03
11 1 2.00 + + + −− 3a DRB1 01 DQB1 02 DRB1 16 DQB1 03
12 1 3.00 −− + −− 0—
13 1 8.00 + + −−− 3c DRB1∗03 DQB1∗03 DRB1∗04 DQB1∗02
14 0 1.50 + + + −− 3b DRB1∗04-DQB1∗03 DRB1 07 DQB1 02
15 0 2.00 − + −−− 3c DRB1∗03-DQB1∗02 DRB1 06 DQB1 05
16 1 2.50 + − + −− 0D R B 1 ∗03 DQB1∗02 DRB1∗09 DQB1∗02
17 1 9.00 −− − − −3b DRB1∗03 DQB1∗02 DRB1∗04 DQB1∗03
18 0 5.00 + − + −− 3c DRB1 01 DQB1 04 DRB1∗03 DQB1∗02
19 1 8.50 + − ++ − 3b DRB1∗011DQB1∗03 DRB1∗011DQB1∗02
20 0 10.00 −− + −− 3a DRB1∗03 DQB1∗02 DRB1∗07 DQB1∗03
21 1 6.50 + + + −− 3c DRB1∗03 DQB1∗02 DRB1∗13 DQB1∗03
22 1 2.50 + + + −− 3c DRB1∗03 DQB1∗03 DRB1∗04 DQB1∗02
23 0 8.50 + − + −− 3a DRB1∗03 DQB1∗03 DRB1∗04 DQB1∗02
24 0 11.00 + + −−− 3a DRB1∗03 DQB1∗02 DRB1∗03 DQB1∗02
25 0 9.00 + + + −− 3c DRB1∗03 DQB1∗02 DRB1∗03 DQB1∗02
26 0 8.50 + + + −− 3b DRB1∗07 DQB1∗03 DRB1∗15 DQB1∗06
27 1 12.00 + −−−− 3c DRB1∗03 DQB1∗03 DRB1∗04 DQB1∗02
Maybe such a small number of positive results is caused by
our study inclusion criteria (having both disorders: T1DM
and CD). The second possible explanation of this ﬁnding
is the fact that children included to the study were rather
young (only 3 of them had the T1DM-onset above 10 years)
and thyroid disorders usually developed in older age. In two
(8%) of 27 children, the diagnosis of Hashimoto’s disease
was made on the basis of the serum ﬁndings and ultrasound
images. All these patients had negative screening results at
T1DM onset and also were euthyroid and asymptomatic at
the time of diagnosis. Data coming from literature pointed
that the asymptomatic course of the disease is rather typical
and indicated the beneﬁts of annual TSH screening to hy-
pothyroidism development [24].
Similar to previously investigated Caucasian popula-
tions, also in our study haplotypes DRB1∗04-DQB1∗03
and DRB1∗03-DQB1∗02 revealed the predominance, since
these are most strongly connected with T1DM haplotypes
[25]. Nevertheless, in the studied group of children with co-
existing CD and T1DM, we observed more frequent pres-
enceofalleleDQB1∗02comparedwithDQB1∗03(59%ver-
sus 33%, resp.). Such predominance of allele DQB1∗02 has
not been noted in our previous study concerning a genetic
susceptibility to T1DM in the same population (65% ver-
sus 62%, resp.) [26]. It conﬁrms earlier observations that the
most strongly connected with CD allele is DQB1∗02, which
is present in about 90% of CD patients [27, 28]. The high
importance of the allele DQB1∗02 in developing CD espe-
cially conﬁrms the Bao study [25]. In this study it was shown
that approximately 1 out of 3 patients with T1DM, who are
DQB1∗02 homozygous, expresses tTG-antibodies, and half
of them have celiac disease on biopsy. In our study group,
we had only 2 children expressing DQB1∗02 homozygosity.
In both cases, the biopsy was positive: stage 3a and 3c were
recognized.
Diabetes-associated autoantibodies were found in most
subjects at the time of T1DM presentation. Our group of
patients is positive to all antibodies: GADA, IA2A, and IAA;
(33%)seemstoberatherlargeincomparisontoagrouppre-
sented for example by Sabbah et al. (2, 1%) [29]. The expla-
nation for such a large group of children positive to multi-
ple autoantibodies could be the fact of having additionally
2 or 3 autoimmune disorders and an individually increased
tendency to autoimmunization. Furthermore, we noted the
GADA dominance in comparison to other markers. Prob-
ably these both facts can result from more frequent pres-
ence of the allele DRB1∗03 in the studied group. The allele
DRB1∗03 is known as the most classic haplotype connectedGrazyna Deja et al. 5
with a diﬀerent form of autoimmunization and a generally
increased tendency to produce autoantibodies. GADA is also
detected more frequently and in higher titer in subjects with
haplotype DRB1∗03 [30, 31]. But because of a rather small
number of children comprising our study group, it is not
possible to make an obvious conclusion based on statistically
signiﬁcant calculations. It indeed makes a limitation of our
study and indicates the necessity of continuation of our ob-
servation to obtain results of more subjects with T1DM and
CD.
5. CONCLUSION
In conclusion, the high-comorbidity ratio of CD and thy-
roiditis in the course of T1DM, especially in a latent and
silent form, demand regular screening tests, especially in the
ﬁrst years after T1DM-onset. The increase in the number
of patients with T1DM and CD and longer observations
are needed to assess the risk factors inﬂuencing the time of
CD onset. It is especially important in the context that the
newest data coming from study performed in 7 big European
Diabetic Centers conﬁrmed rapidly the increasing trend of
prevalence of both disorders [32]a n db e c a u s eo fo n l yaf e w
data on the predictive value and risk factors of CD in T1DM
populations published so far [33].
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